$AKBA
Akebia Therapeutics, Inc. Stock $akba

$akba Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000162828022028242 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$55.18M	$48.96M
YoY Change	-7.42%	0.43%
Cost Of Revenue	-$11.25M	$37.95M
YoY Change	-126.56%	138.0%
Gross Profit	$66.43M	$11.02M
YoY Change	285.43%	-66.42%
Gross Profit Margin	120.39%	22.5%
Selling, General & Admin	$30.65M	$30.92M
YoY Change	-31.63%	-33.3%
% of Gross Profit	46.13%	280.64%
Research & Development	$31.90M	$27.35M
YoY Change	7.94%	-32.42%
% of Gross Profit	48.02%	248.25%
Depreciation & Amortization	$9.419M	$9.424M
YoY Change	-0.36%	-0.63%
% of Gross Profit	14.18%	85.54%
Operating Expenses	$71.56M	$59.19M
YoY Change	-14.19%	-32.51%
Operating Profit	-$5.128M	-$48.17M
YoY Change	-92.25%	-12.23%
Interest Expense	-$1.636M	-$3.952M
YoY Change	-67.81%	-22.28%
% of Operating Profit
Other Income/Expense, Net	$434.0K	$1.167M
YoY Change	-22.5%	173.3%
Pretax Income	-$7.552M	-$51.87M
YoY Change	-89.31%	-12.9%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$7.552M	-$51.87M
YoY Change	-89.31%	-12.9%
Net Earnings / Revenue	-13.69%	-105.92%
Basic Earnings Per Share		-$0.28
Diluted Earnings Per Share	-$0.04	-$0.28
COMMON SHARES
Basic Shares Outstanding	184.0M shares	183.8M shares
Diluted Shares Outstanding		183.9M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.47M	$144.8M
YoY Change	-39.61%	-30.14%
Cash & Equivalents	$90.47M	$144.8M
Short-Term Investments
Other Short-Term Assets	$33.54M	$29.62M
YoY Change	1.21%	-25.02%
Inventory	$21.76M	$40.04M
Prepaid Expenses	$15.60M
Receivables	$39.18M	$23.09M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$184.9M	$237.5M
YoY Change	-32.01%	-28.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.214M	$5.622M
YoY Change	-22.8%	-21.87%
Goodwill	$55.10M	$55.10M
YoY Change	0.0%	0.0%
Intangibles	$72.08M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.372M	$26.28M
YoY Change	-89.2%	-62.25%
Total Long-Term Assets	$166.9M	$198.4M
YoY Change	-34.18%	-27.11%
TOTAL ASSETS
Total Short-Term Assets	$184.9M	$237.5M
Total Long-Term Assets	$166.9M	$198.4M
Total Assets	$351.8M	$435.9M
YoY Change	-33.05%	-27.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.02M	$19.71M
YoY Change	-46.35%	-31.59%
Accrued Expenses	$71.00M	$87.36M
YoY Change	-32.03%	-39.63%
Deferred Revenue	$3.738M	$1.265M
YoY Change	-82.12%	-91.94%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$32.00M	$65.95M
YoY Change	-67.19%
Total Short-Term Liabilities	$124.8M	$188.0M
YoY Change	-51.36%	-0.66%
LONG-TERM LIABILITIES
Long-Term Debt	$34.08M	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$12.16M	$74.31M
YoY Change	-85.26%	-3.98%
Total Long-Term Liabilities	$46.24M	$74.31M
YoY Change	-43.97%	-57.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$124.8M	$188.0M
Total Long-Term Liabilities	$46.24M	$74.31M
Total Liabilities	$342.5M	$422.0M
YoY Change	-23.74%	-9.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.553B	-$1.545B
YoY Change	6.34%	11.2%
Common Stock	$1.562B	$1.559B
YoY Change	1.66%	2.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.342M	$13.85M
YoY Change
Total Liabilities & Shareholders Equity	$351.8M	$435.9M
YoY Change	-33.05%	-27.62%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$7.552M	-$51.87M
YoY Change	-89.31%	-12.9%
Depreciation, Depletion And Amortization	$9.419M	$9.424M
YoY Change	-0.36%	-0.63%
Cash From Operating Activities	-$54.68M	$33.81M
YoY Change	-12.94%	-160.08%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.000K	-32.94M
YoY Change	-100.02%	-299.84%
NET CHANGE
Cash From Operating Activities	-54.68M	33.81M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	-1.000K	-32.94M
Net Change In Cash	-54.68M	868.0K
YoY Change	-4.75%	-102.18%
FREE CASH FLOW
Cash From Operating Activities	-$54.68M	$33.81M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$54.68M	$33.81M
YoY Change	-12.94%	-160.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Inventory Write Down InventoryWriteDown	7100000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001517022
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q3	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36352
	dei	Entity Registrant Name EntityRegistrantName	AKEBIA THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8756903
	dei	Entity Address Address Line1 EntityAddressAddressLine1	245 First Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	871-2098
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
	dei	Trading Symbol TradingSymbol	AKBA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	183962083	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144761000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149800000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	40039000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	38195000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23094000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	50875000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29618000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33140000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	237512000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	272010000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5622000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6754000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30337000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33852000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	55053000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	55053000	usd
CY2022Q3	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	81095000	usd
CY2021Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	108127000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	26275000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	49754000	usd
CY2022Q3	us-gaap	Assets Assets	435894000	usd
CY2021Q4	us-gaap	Assets Assets	525550000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	19708000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	33588000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87364000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	104456000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1265000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	20906000	usd
CY2022Q3	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	13681000	usd
CY2021Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	0	usd
CY2022Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	65947000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	97543000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	187965000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	256493000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	43296000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	21474000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30683000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33703000	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	760000	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1820000	usd
CY2022Q3	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	58236000	usd
CY2021Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	53079000	usd
CY2022Q3	us-gaap	Contract With Customer Refund Liability Noncurrent ContractWithCustomerRefundLiabilityNoncurrent	26788000	usd
CY2021Q4	us-gaap	Contract With Customer Refund Liability Noncurrent ContractWithCustomerRefundLiabilityNoncurrent	0	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	74313000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	82525000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	422041000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	449094000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	183951583	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	183951583	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177000963	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	177000963	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1559206000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1536800000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1545361000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1460351000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	13853000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	76456000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	435894000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	525550000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48964000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48756000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	237422000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	153973000	usd
CY2022Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	28936000	usd
CY2021Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	6933000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	60859000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	76012000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9011000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9011000	usd
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	27032000	usd
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	27032000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	37947000	usd
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	15944000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	87891000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	103044000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27350000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40471000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	97210000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118296000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30918000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46357000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	108052000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	129336000	usd
CY2022Q3	akba	License Expense LicenseExpense	743000	usd
CY2021Q3	akba	License Expense LicenseExpense	870000	usd
	akba	License Expense LicenseExpense	2323000	usd
	akba	License Expense LicenseExpense	2460000	usd
CY2022Q3	us-gaap	Restructuring Charges RestructuringCharges	180000	usd
CY2021Q3	us-gaap	Restructuring Charges RestructuringCharges	0	usd
	us-gaap	Restructuring Charges RestructuringCharges	14711000	usd
	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	59191000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	87698000	usd
	us-gaap	Operating Expenses OperatingExpenses	222296000	usd
	us-gaap	Operating Expenses OperatingExpenses	250092000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-48174000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-54886000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72765000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-199163000	usd
CY2022Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-3952000	usd
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5085000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14051000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14853000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1167000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	427000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2712000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1854000	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-906000	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-906000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-51865000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-51865000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-59544000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-59544000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-85010000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-85010000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-212162000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-212162000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.30
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	183882446	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	183882446	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173782151	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173782151	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	182375443	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	182375443	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	163050769	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	163050769	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-51865000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-59544000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-85010000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212162000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51865000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-59544000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85010000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-212169000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	247618000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29498000	usd
CY2021Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	367000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5992000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	213891000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37266000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6515000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-83038000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	174631000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16092000	usd
CY2021Q3	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	379000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5592000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-59544000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	137150000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	76456000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7178000	usd
CY2022Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	367000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4536000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62421000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	26116000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6841000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	67000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	29276000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	62300000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3375000	usd
CY2022Q3	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	43000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-51865000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	13853000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-85010000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-212162000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1246000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1485000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27032000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27032000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	15000	usd
	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	6352000	usd
	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	6779000	usd
	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	1195000	usd
	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	425000	usd
	akba	Contract With Customer Non Cash Revenue Recognized ContractWithCustomerNonCashRevenueRecognized	9550000	usd
	akba	Contract With Customer Non Cash Revenue Recognized ContractWithCustomerNonCashRevenueRecognized	0	usd
	akba	Noncash Research And Development Expense NoncashResearchAndDevelopmentExpense	3941000	usd
	akba	Noncash Research And Development Expense NoncashResearchAndDevelopmentExpense	0	usd
	akba	Noncash Interest Expense NoncashInterestExpense	1467000	usd
	akba	Noncash Interest Expense NoncashInterestExpense	852000	usd
	us-gaap	Straight Line Rent StraightLineRent	1818000	usd
	us-gaap	Straight Line Rent StraightLineRent	1415000	usd
	akba	Noncash Gain Loss On Extinguishment Of Debt NoncashGainLossOnExtinguishmentOfDebt	-406000	usd
	akba	Noncash Gain Loss On Extinguishment Of Debt NoncashGainLossOnExtinguishmentOfDebt	0	usd
	akba	Fair Value Adjustment To Inventory FairValueAdjustmentToInventory	0	usd
	akba	Fair Value Adjustment To Inventory FairValueAdjustmentToInventory	21575000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	10002000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	7126000	usd
	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	12422000	usd
	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	15376000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	14808000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	18099000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-1060000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-490000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-27781000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22837000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1405000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	35282000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9131000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	25020000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-14817000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4728000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-17420000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-14933000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-22364000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15099000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1771000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	1173000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2181000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3098000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-14820000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18475000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-190157000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	114000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	40000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-114000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39941000	usd
	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	0	usd
	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44783000	usd
	akba	Proceeds From Refund Liability To Contract With Customer ProceedsFromRefundLiabilityToContractWithCustomer	40000000	usd
	akba	Proceeds From Refund Liability To Contract With Customer ProceedsFromRefundLiabilityToContractWithCustomer	0	usd
	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	7122000	usd
	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	82799000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	410000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	746000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	67000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	33000000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14599000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	128328000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3990000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21888000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151839000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231132000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147849000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	209244000	usd
	akba	Deferred Unpaid Offering Costs DeferredUnpaidOfferingCosts	0	usd
	akba	Deferred Unpaid Offering Costs DeferredUnpaidOfferingCosts	57000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Organization and Operations<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. Akebia is a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease. The Company has one commercial product, Auryxia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ferric citrate), which is approved by the U.S. Food and Drug Administration, or FDA, and marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with chronic kidney disease, or CKD, on dialysis, or DD-CKD, and the treatment of iron deficiency anemia, or IDA, in adult patients with CKD not on dialysis, or NDD-CKD. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients for the improvement of hyperphosphatemia in such patients with DD-CKD and NDD-CKD under the trade name Riona (ferric citrate hydrate).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vadadustat, the Company’s lead investigational product candidate, is an investigational oral hypoxia-inducible factor prolyl hydroxylase, or HIF-PH, inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. On March 29, 2022, the Company received a complete response letter, or CRL, from the FDA. The CRL provided that the FDA had completed its review of the Company's new drug application, or NDA, for vadadustat for the treatment of anemia due to CKD in adult patients and had determined that it could not approve the NDA in its present form. In July 2022, the Company held an end of review meeting with the FDA to inform the Company's next steps with respect to the potential U.S. approval of vadadustat, if any, and in October 2022, the Company submitted a Formal Dispute Resolution Request, or FDRR, with the FDA. The FDRR focuses on the favorable balance between the benefits and risks of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis in light of safety concerns expressed by the FDA in the CRL related to the rate of adjudicated thromboembolic events driven by vascular access thrombosis for vadadustat compared to the active comparator and the risk of drug-induced liver injury.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 12, 2022, the Company received notice from its former collaboration partner, Otsuka Pharmaceutical Co. Ltd., or Otsuka, that Otsuka had elected to terminate the Collaboration and License Agreement dated December 18, 2016, or the Otsuka U.S. Agreement, and the Collaboration and License Agreement dated April 25, 2017, or the Otsuka International Agreement. On June 30, 2022, the Company and Otsuka entered into a Termination and Settlement Agreement, or the Termination Agreement, pursuant to which, among other things, the Company and Otsuka agreed to terminate the Otsuka U.S. Agreement and the Otsuka International Agreement as of June 30, 2022 (see Note 4 for further details). In October 2021, Otsuka submitted a Marketing Authorization Application, or MAA, for vadadustat for the treatment of anemia due to CKD in adult patients with DD-CKD and NDD-CKD to the European Medicines Agency, or EMA</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In connection with the Termination Agreement, Otsuka transferred the MAA for vadadustat with the EMA to the Company. Vadadustat is approved in Japan as a treatment for anemia due to CKD in both DD-CKD and NDD-CKD patients under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and marketed and sold in Japan by Mitsubishi Tanabe Pharma Corporation, or MTPC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company continues to explore additional development opportunities to expand its pipeline and portfolio of novel therapeutics. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, commercializing Auryxia, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan from the Company’s Japanese partners, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively JT and Torii, in December 2018. Additionally, following regulatory approval of vadadustat in Japan, the Company began recognizing royalty revenues from MTPC from the sale of Vafseo in August 2020. In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or HCR, or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under its Collaboration Agreement with MTPC, or the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 6 for additional information). The Company has not generated a profit to date, and may never generate profits, from product sales. Vadadustat and the Company’s other potential product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market vadadustat and its other potential product candidates. If the Company does not successfully commercialize Auryxia, vadadustat, if approved, or any other potential product candidate, it may be unable to achieve profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going Concern</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s management completed its going concern assessment in accordance with Accounting Standards Codification, or ASC, 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, or ASC 205-40. Pursuant to the requirements of ASC 205-40, the Company’s management must evaluate whether there are conditions or events, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When substantial doubt exists under this methodology, the Company’s management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of the Company’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of September 30, 2022, the Company had cash and cash equivalents of approximately $144.8 million. The Company believes that its cash resources will be sufficient to allow the Company to fund its current operating plan through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q. However, the Company's operating plan includes assumptions pertaining to cost avoidance measures and the reduction of overhead costs that would result from the planned amendment of contractual arrangements with certain supply and collaboration partners, and the reduction of operating expenses. Therefore, because these cost avoidance measures and certain other elements of the Company's operating plan are outside of its control, including the planned amendment of contractual arrangements with certain supply and collaboration partners, and the reduction of operating expenses, there is uncertainty as to whether the Company's cash resources will be adequate to support its operations for a period through at least the next twelve months from the date of issuance of these financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, on July 15, 2022, or the Effective Date, the Company entered into the Second Amendment and Waiver with BioPharma Credit PLC, or the Collateral Agent, BPCR Limited Partnership, as a Lender, and BioPharma Credit Investments V (Master) LP, as a Lender, or the Second Amendment and Waiver, which amends and waives certain provisions of the loan agreement entered on November 11, 2019, between the Company, with Keryx Biopharmaceuticals, Inc., or Keryx, as guarantor, and the Collateral Agent, as collateral agent and a lender, and BioPharma Credit Investments V (Master) LP as a lender, or the Loan Agreement, as amended by the First Amendment and Waiver among the Collateral Agent, the Lenders and the Company, dated February 18, 2022, or the First Amendment and Waiver. The Collateral Agent and the Lenders are collectively referred to as Pharmakon (see Note 11). Pursuant to the Second Amendment and Waiver, on the Effective Date, the Company made prepayments totaling $25.0 million together with a prepayment premium of $0.5 million plus all accrued and unpaid interest on such prepayments of principal to the Effective Date, and Pharmakon agreed to waive or modify certain covenants in the Loan Agreement (see Note 11). If an event of default occurs and is continuing under the Loan Agreement, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement, which the Company may not have the available cash resources to repay at such time. For example, pursuant to covenants in the Loan Agreement, the Company's Annual Reports on Form 10-K must not be subject to any qualification as a going concern. If any of the Company's future Annual Reports on Form 10-K is subject to any qualification related to going concern, it will result in an event of default under the Loan Agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. Management’s plans to alleviate the conditions that raise substantial doubt through cost avoidance measures, including amending contractual arrangements with certain supply and collaboration partners, and reducing operating expenses, for the Company to continue as a going concern for a period of twelve months from the date the financial statements are issued. However, the Company has concluded that the likelihood that its plan to extend its cash runway from one or more of these approaches will be successful, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities, other than obligations under the Loan Agreement classified as current, that might result from the outcome of the uncertainties described above.</span></div>
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144800000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	-1591000	usd
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	113090000	usd
CY2021Q3	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45891000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	29574000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	20363000	usd
CY2022Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, refund liabilities to customers, other non-current liabilities, including the excess purchase commitment liability, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span></div>
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	28378000	usd
	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	76606000	usd
	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	-215000	usd
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	77474000	usd
CY2022Q3	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	27295000	usd
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	41363000	usd
	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	119209000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1265000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	43296000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	44561000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5047000	usd
CY2021Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9159000	usd
CY2021Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
CY2022Q3	akba	Contract With Customer Refund Liability Amortization Of Discount ContractWithCustomerRefundLiabilityAmortizationOfDiscount	1100000	usd
	akba	Contract With Customer Refund Liability Amortization Of Discount ContractWithCustomerRefundLiabilityAmortizationOfDiscount	2300000	usd
CY2022Q3	akba	Contract With Customer Refund Liability Amortization Of Deferred Gain ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain	900000	usd
	akba	Contract With Customer Refund Liability Amortization Of Deferred Gain ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain	1800000	usd
CY2022Q3	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	13700000	usd
CY2022Q2	akba	Restructuring And Related Cost Number Of Positions Exclusive Of Open Positions Approved For Elimination Percent RestructuringAndRelatedCostNumberOfPositionsExclusiveOfOpenPositionsApprovedForEliminationPercent	0.42
CY2022Q2	akba	Restructuring And Related Cost Number Of Positions Inclusive Of Open Positions Approved For Elimination Percent RestructuringAndRelatedCostNumberOfPositionsInclusiveOfOpenPositionsApprovedForEliminationPercent	0.47
CY2022Q3	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	14700000	usd
CY2022Q3	us-gaap	Restructuring Charges RestructuringCharges	200000	usd
	us-gaap	Restructuring Charges RestructuringCharges	14700000	usd
	us-gaap	Severance Costs1 SeveranceCosts1	11400000	usd
CY2022Q3	us-gaap	Severance Costs1 SeveranceCosts1	11400000	usd
CY2022Q3	us-gaap	Other Restructuring Costs OtherRestructuringCosts	3300000	usd
	us-gaap	Other Restructuring Costs OtherRestructuringCosts	3300000	usd
CY2021Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	53079000	usd
CY2021Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	usd
	us-gaap	Restructuring Charges RestructuringCharges	14711000	usd
	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	3253000	usd
	akba	Payments For Restructuring And Adjustments PaymentsForRestructuringAndAdjustments	7220000	usd
CY2022Q3	us-gaap	Restructuring Reserve RestructuringReserve	4238000	usd
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Annual Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity	13000000	usd
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Aggregate Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity	150000000	usd
CY2021Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44800000	usd
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	44800000	usd
CY2022Q3	akba	Contractual Arrangement Royalties Agreement Interest Rate Effective Percentage ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage	0.136
CY2022Q3	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-350000	usd
	akba	Contractual Arrangement Royalties Agreement Royalties Earned And Payable ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable	1195000	usd
	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	6352000	usd
CY2022Q3	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	58236000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1820000	usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-710000	usd
CY2022Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1110000	usd
CY2022Q2	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
CY2022Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1110000	usd
CY2022Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	760000	usd
CY2022Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	397000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1763000	usd
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	32855000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	62635000	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	18970000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14661000	usd
CY2022Q3	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	52222000	usd
CY2021Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	79059000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	40039000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	38195000	usd
CY2022Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	12183000	usd
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	40864000	usd
CY2022Q3	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	52222000	usd
CY2021Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	79059000	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	2600000	usd
CY2021Q3	us-gaap	Inventory Write Down InventoryWriteDown	1700000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	10000000	usd
	akba	Inventory Adjustments To Previous Reserves InventoryAdjustmentsToPreviousReserves	14800000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	213603000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	132508000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	81095000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	213603000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	105476000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	108127000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	27000000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	55100000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	55100000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q3	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	25222000	usd
CY2021Q4	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	26624000	usd
CY2022Q3	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	8652000	usd
CY2021Q4	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	14036000	usd
CY2022Q3	akba	Collaborative Arrangement Accrued Liability CollaborativeArrangementAccruedLiability	19550000	usd
CY2021Q4	akba	Collaborative Arrangement Accrued Liability CollaborativeArrangementAccruedLiability	22654000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9140000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15863000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4260000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4802000	usd
CY2022Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2916000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3472000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1725000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1899000	usd
CY2022Q3	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	3167000	usd
CY2021Q4	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	3843000	usd
CY2022Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	4238000	usd
CY2021Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8494000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11263000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87364000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	104456000	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	32000000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	35000000	usd
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	67000000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1053000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	65947000	usd
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	183951583	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	183951583	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177000963	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	177000963	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	akba	Number Of Stock Incentive Plans NumberOfStockIncentivePlans	1	stock_incentive_plan
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1800000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1700000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	5400000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	5000000	usd
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	1800000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	1800000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	5500000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	5300000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1837000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	461000	usd
CY2022Q3	akba	Lessee Operating Lease Liability Payments Net Reminder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear	1376000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6954000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	307000	usd
CY2022Q3	akba	Lessee Operating Lease Liability Payments Due Net Year One LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne	6647000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8167000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	usd
CY2022Q3	akba	Lessee Operating Lease Liability Payments Due Net Year Two LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo	8167000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8293000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	usd
CY2022Q3	akba	Lessee Operating Lease Liability Payments Due Net Year Three LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree	8293000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6571000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	usd
CY2022Q3	akba	Lessee Operating Lease Liability Payments Due Net Year Four LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour	6571000	usd
CY2022Q3	akba	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	12200000	usd
CY2022Q3	akba	Lessor Operating Lease Payment To Be Received Due After Year Four LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour	0	usd
CY2022Q3	akba	Lessee Operating Lease Liability Payments Due Net After Year Four LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour	12200000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	44022000	usd
CY2022Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	768000	usd
CY2022Q3	akba	Lessee Operating Lease Liability Payments Due Net LesseeOperatingLeaseLiabilityPaymentsDueNet	43254000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	44022000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8733000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	35289000	usd
CY2022Q3	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	13200000	usd
CY2022Q3	akba	Inventory Adjustments To Previous Reserves InventoryAdjustmentsToPreviousReserves	5800000	usd
CY2022Q3	akba	Inventory Adjustments To Previous Reserves InventoryAdjustmentsToPreviousReserves	5800000	usd
CY2022Q1	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	-800000	usd
CY2022Q1	akba	Inventory Adjustments To Previous Reserves InventoryAdjustmentsToPreviousReserves	3200000	usd
CY2022Q3	akba	Purchase Committed Program Remaining Contract Costs PurchaseCommittedProgramRemainingContractCosts	4600000	usd
	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	176300000	usd
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18816539	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17482066	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001628280-22-028242-index-headers.html	Edgar Link	pending
0001628280-22-028242-index.html	Edgar Link	pending
0001628280-22-028242.txt	Edgar Link	pending
0001628280-22-028242-xbrl.zip	Edgar Link	pending
akba-20220930.htm	Edgar Link	pending
akba-20220930.xsd	Edgar Link	pending
exhibit102-formofformofame.htm	Edgar Link	pending
exhibit311-q32022.htm	Edgar Link	pending
exhibit312-q32022.htm	Edgar Link	pending
akba-20220930_cal.xml	Edgar Link	unprocessable
akba-20220930_def.xml	Edgar Link	unprocessable
akba-20220930_pre.xml	Edgar Link	unprocessable
akba-20220930_lab.xml	Edgar Link	unprocessable
akba-20220930_htm.xml	Edgar Link	completed
exhibit321-q32022.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AKBA
Akebia Therapeutics, Inc. Stock $akba

2022 Q4 Form 10-Q Financial Statement

#000162828022028242 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA Akebia Therapeutics, Inc. Stock $akba

2022 Q4 Form 10-Q Financial Statement

#000162828022028242 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA
Akebia Therapeutics, Inc. Stock $akba